Norges Bank
CRVS icon

Norges Bank’s Corvus Pharmaceuticals CRVS Stock Holding History

Norges Bank’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,200
Closed -$60K – 2151
2016
Q2 		$60K Sell
4,200
-15,800
-79% -$213K ﹤0.01% 2170
2016
Q1 		$290K Buy
+20,000
New +$287K ﹤0.01% 2157

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Norges Bank's CRVS Position: Q3 2016 in Review

Norges Bank sold out of Corvus Pharmaceuticals (CRVS) in Q3 2016, closing a stake of 4,200 shares — an estimated $60K sold.

Norges Bank first reported a position in CRVS in Q1 2016 and held it in 2 quarters. The position peaked at $290K in Q1 2016. 45 funds tracked by Wall St. Rank hold CRVS as of Q3 2016.

  • Norges Bank reported no remaining Corvus Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Norges Bank sold 4,200 Corvus Pharmaceuticals shares in Q3 2016, an estimated $60K.
  • Norges Bank first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Norges Bank's Corvus Pharmaceuticals position peaked at $290K in Q1 2016.
  • 45 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2016.

Based on Norges Bank's 13F filing for Q3 2016, filed 14 Nov 2016.